Kathleen Farquhar
Medical · Commerce Township, MINPI 1962569467
Payments from drug & device makers
Across 89 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$335
- Pfizer$220
- AstraZeneca$142
- AbbVie$118
- Amgen$96
- Axsome Therapeutics, Inc.$86
- plus $608 from 18 others
What the payments were for
- Food & beverage$1,605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $335 |
| Pfizer | 11 | $220 |
| AstraZeneca(2 entities) | 9 | $142 |
| AbbVie | 6 | $118 |
| Amgen | 5 | $96 |
| Axsome Therapeutics, Inc. | 4 | $86 |
| Abbott | 4 | $82 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Astellas Pharma US Inc | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Boehringer Ingelheim | 2 | $48 |
| GSK | 2 | $34 |
| Noven Therapeutics, LLC | 2 | $33 |
| Lilly USA, LLC | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Bausch Health US, LLC | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,605 in reported general payments places this provider in the 70th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $24,379 |
| OzempicSemaglutide | 14 | $23,699 |
| MounjaroTirzepatide | 16 | $20,511 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,658 |
| Atorvastatin Calcium | 108 | $1,135 |
| Levothyroxine Sodium | 89 | $1,087 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $1,006 |
| Pantoprazole Sodium | 39 | $922 |
| Ondansetron OdtOndansetron | 14 | $849 |
| Trazodone Hcl | 33 | $806 |
| Duloxetine Hcl | 27 | $743 |
| Nifedipine ErNifedipine | 12 | $704 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $639 |
| Omeprazole | 39 | $621 |
| Lisinopril | 71 | $606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $34 | $24,37926 claims |
| Novo NordiskOzempic | $335 | $23,69914 claims |
| Lilly USA, LLCMounjaro | $31 | $20,51116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 755 medical providers in Michigan.
Other medical in Commerce Township
- Alexandria RednerCommerce Township$12K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.